Structure-based design of novel class II c-Met inhibitors: 1. Identification of pyrazolone-based derivatives.
Norman, M.H., Liu, L., Lee, M., Xi, N., Fellows, I., D'Angelo, N.D., Dominguez, C., Rex, K., Bellon, S.F., Kim, T.S., Dussault, I.(2012) J Med Chem 55: 1858-1867
- PubMed: 22320343 
- DOI: 10.1021/jm201330u
- Primary Citation of Related Structures:  
3U6H, 3U6I, 3U6J - PubMed Abstract: 
Deregulation of c-Met receptor tyrosine kinase activity leads to tumorigenesis and metastasis in animal models. More importantly, the identification of activating mutations in c-Met, as well as MET gene amplification in human cancers, points to c-Met as an important target for cancer therapy ...